Registry of patients with autoimmune liver diseases in St. Petersburg: clinical and epidemiological data
- Authors: Bakulin I.G.1, Burlakova S.A.1, Skazyvaeva E.V.1, Skalinskaya M.I.1
-
Affiliations:
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 16, No 2 (2024)
- Pages: 61-72
- Section: Original research
- URL: https://journals.rcsi.science/vszgmu/article/view/262694
- DOI: https://doi.org/10.17816/mechnikov627505
- ID: 262694
Cite item
Abstract
BACKGROUND: The problem of autoimmune liver diseases, which include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and their overlap syndromes is an urgent problem of modern medicine. This is associated with an increase in the incidence and prevalence of these nosologies in different regions of the world. Absence of an established etiological factor, prolonged asymptomatic or low-symptomatic course, lack of pathognomonic clinical picture, imperfect diagnostic criteria, insufficient awareness of physicians lead to late diagnosis of autoimmune liver diseases and, accordingly, untimely initiation of treatment, which often reduces its effectiveness, affecting the further prognosis and survival rate for this group of patients. Patients with autoimmune liver diseases require long-term, often lifelong therapy and dispensary observation. Epidemiological registries along with autoimmune liver diseases registries, including various nosologies of autoimmune liver diseases, form an important database on the incidence, clinical features, development and course of the disease, variants of therapy and response to therapy, presence of extrahepatic manifestations as well as allow analysis of all data in dynamics.
AIM: To analize data on various nosologies of autoimmune liver diseases, demographics, clinical symptoms, timing of the first symptoms, timing of diagnosis, and the nature of extrahepatic manifestations.
MATERIALS AND METHODS: This article presents data from the autoimmune liver diseases Register of the North-West Hepatology Centre (North-West Autoimmune Liver Diseases Register) of the North-Western State Medical University named after I.I. Mechnikov.
RESULTS: The study obtained data on the nosological structure, demographic characteristics, timing of diagnosis verification, clinical symptoms and extrahepatic manifestations of autoimmune liver diseases.
CONCLUSIONS: Establishing registers of autoimmune liver diseases, providing information about patients with these diseases, will help to assess the effectiveness of examination and treatment methods, factors affecting the course and prognosis of the disease. Analysis of the data obtained will help to develop screening programs, diagnostic algorithms and differential diagnostics of autoimmune liver diseases, which, in turn, will facilitate the diagnostic process, shorten the time of diagnosis, make it possible to start therapy earlier and, consequently, improve the prognosis and survival rate for this group of patients.
Full Text
##article.viewOnOriginalSite##About the authors
Igor G. Bakulin
North-Western State Medical University named after I.I. Mechnikov
Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021
SPIN-code: 5283-2032
MD, Dr. Sci. (Med.), Professor
Russian Federation, Saint PetersburgSvetlana A. Burlakova
North-Western State Medical University named after I.I. Mechnikov
Email: burlakova20012010@gmail.com
ORCID iD: 0000-0002-6659-2622
SPIN-code: 3550-3719
Russian Federation, Saint Petersburg
Ekaterina V. Skazyvaeva
North-Western State Medical University named after I.I. Mechnikov
Email: skazyvaeva@yandex.ru
ORCID iD: 0000-0002-8563-6870
SPIN-code: 5882-1152
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, Saint PetersburgMaria I. Skalinskaya
North-Western State Medical University named after I.I. Mechnikov
Author for correspondence.
Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-0769-8176
SPIN-code: 2596-5555
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, Saint PetersburgReferences
- Galoosian A, Hanlon C, Zhang J, et al. Clinical updates in primary biliary cholangitis: Trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 2020;8(1):49–60. doi: 10.14218/JCTH.2019.00049
- Sarcognato S, Sacchi D, Grillo F, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021;113(3):170–184. doi: 10.32074/1591-951X-245
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172. doi: 10.1016/j.jhep.2017.03.022
- Sucher E, Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res. 2019;2019:9437043. doi: 10.1155/2019/9437043
- Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671–722. doi: 10.1002/hep.31065
- Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53(5):1590–1599. doi: 10.1002/hep.24247
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761–806. doi: 10.1016/j.jhep.2022.05.011 Erratum in: J Hepatol. 2023;79(5):1339. doi: 10.1016/j.jhep.2023.09.005
- Lu M, Li J, Haller IV, et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States Health Systems. Clin Gastroenterol Hepatol. 2018;16(8):1333–1341.e6. doi: 10.1016/j.cgh.2017.10.018
- Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis. 2015;33 Suppl 2:2–12. doi: 10.1159/000440705
- Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60(3):612–617. doi: 10.1016/j.jhep.2013.10.020
- Wang QX, Yan L, Ma X. Autoimmune hepatitis in the Asia-Pacific Area. J Clin Transl Hepatol. 2018;6(1):48–56. doi: 10.14218/JCTH.2017.00032
- Tanaka A, Mori M, Matsumoto K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res. 2019;49(8):881–889. doi: 10.1111/hepr.13342
- Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886. doi: 10.1056/NEJM200006223422506
- Oliveira RC, Rodrigues S, Santo JE. Hepatologia Em Rede. A Portuguese Association for the Study of the Liver (APEF) Initiative for the Improvement of Research in Liver Disease in Portugal. GE Port J Gastroenterol. 2023;30(6):474–476. doi: 10.1159/000531270
- Jeong SH. Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. Clin Mol Hepatol. 2018;24(1):10–19. doi: 10.3350/cmh.2017.0066
- Ludz C, Stirnimann G, Semela D, et al. Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study. Swiss Med Wkly. 2023;153:40102. doi: 10.57187/smw.2023.40102
- Cortez-Pinto H, Liberal R, Lopes S, et al. Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease. United European Gastroenterol J. 2021;9(6):699–706. doi: 10.1002/ueg2.12095
- Nielsen KR, Midjord J, Johannesen HL, Grønbæk H. A nationwide study of autoimmune liver diseases in the Faroe Islands: Incidence, prevalence, and causes of death 2004–2021. Int J Circumpolar Health. 2023;82(1):2221368. doi: 10.1080/22423982.2023.2221368
- Alrubaiy L, Oztumer CA. Setting up a local registry to improve the care of patients with primary biliary cholangitis. Cureus. 2022;14(5):e25247. doi: 10.7759/cureus.25247
- Sivakumar M, Gandhi A, Shakweh E, et al. Widespread gaps in the quality of care for primary biliary cholangitis in UK. Frontline Gastroenterol. 2021;13(1):32–38. doi: 10.1136/flgastro-2020-101713
- Akberova D, Odlntsova A, Abdulganleva D. Clinical and epidemiological characteristics of autoimmune liver diseases. Vrach. 2015;26(12):27–29. EDN: VCOQBP
- Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394–419. doi: 10.1002/hep.30145
- Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2–3):192–197. doi: 10.1007/s12016-014-8427-x
- Muratori P, Fabbri A, Lalanne C, et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol. 2015;27(10):1175–1179. doi: 10.1097/MEG.0000000000000424
- Wong GW, Heneghan MA. Association of extrahepatic manifestations with autoimmune hepatitis. Dig Dis. 2015;33 Suppl 2:25–35. doi: 10.1159/000440707
- de Vries AB, Janse M, Blokzijl H. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21:1956–1971. doi: 10.3748/wjg.v21.i6.1956
- Bakulin IG, Skalinskaya MI, Skazyvaeva EV, et al. Extraintestinal manifestations of inflammatory bowel diseases: modern conception and contribution to the disease insight. Therapy. 2022;8(1(53)):71–93. EDN: RXKJFW doi: 10.18565/therapy.2022.1.71-93
- Bakulin IG, Skalinskaya MI, Skazyvaeva EV. North-Western register of patients with inflammatory bowel diseases: achievements and lessons learned. Koloproktologia. 2022;21(1):37–49. EDN: ITCUJP doi: 10.33878/2073-7556-2022-21-1-37-49